CN104136026B - 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 - Google Patents
包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 Download PDFInfo
- Publication number
- CN104136026B CN104136026B CN201280064763.1A CN201280064763A CN104136026B CN 104136026 B CN104136026 B CN 104136026B CN 201280064763 A CN201280064763 A CN 201280064763A CN 104136026 B CN104136026 B CN 104136026B
- Authority
- CN
- China
- Prior art keywords
- compound
- mao
- glioma
- cells
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553854P | 2011-10-31 | 2011-10-31 | |
| US61/553,854 | 2011-10-31 | ||
| PCT/US2012/062850 WO2013151584A1 (en) | 2011-10-31 | 2012-10-31 | Compound comprising a mao targeting/ seeker moiety for treating human gliomas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104136026A CN104136026A (zh) | 2014-11-05 |
| CN104136026B true CN104136026B (zh) | 2018-03-02 |
Family
ID=47146760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280064763.1A Expired - Fee Related CN104136026B (zh) | 2011-10-31 | 2012-10-31 | 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10555936B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2804604A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6118808B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102110794B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104136026B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012376221A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2887928A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1204547A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013151584A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6118808B2 (ja) | 2011-10-31 | 2017-04-19 | ザ メソジスト ホスピタル リサーチ インスティテュート | ヒトグリオームを治療するためのmao標的化/探索部分を含む化合物 |
| CN104710433B (zh) * | 2014-01-23 | 2016-08-17 | 南京友怡医药科技有限公司 | 苯丁酸氮芥衍生物、制备方法及应用 |
| US10807944B2 (en) * | 2014-04-04 | 2020-10-20 | University Of Florida Research Foundation, Inc. | HDAC inhibitor compounds and methods of treatment |
| US12245355B2 (en) | 2021-02-19 | 2025-03-04 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994029333A1 (en) * | 1993-06-07 | 1994-12-22 | The Wellcome Foundation Limited | Immunoreactive reagents employing monoamine oxidase |
| WO1998022110A1 (en) * | 1996-11-20 | 1998-05-28 | Virginia Tech Intellectual Properties, Inc. | Prodrugs for the selective inhibition of monoamine oxidase-b |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4913891A (en) * | 1986-04-17 | 1990-04-03 | The United States Of America As Represented By The United States Department Of Energy | Positron emitter labeled enzyme inhibitors |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5612329A (en) | 1995-06-05 | 1997-03-18 | University Of Maryland At Baltimore | Diaziridinylpolyamine anti-cancer agents |
| KR20010102486A (ko) | 1999-03-03 | 2001-11-15 | 데이비드 엠 모이어 | 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제 |
| US6727361B2 (en) | 2000-11-07 | 2004-04-27 | Symyx Technologies, Inc. | Phosphino substituted pyridine amine ligands |
| US6946479B2 (en) | 2002-11-09 | 2005-09-20 | The Procter & Gamble Company | N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones |
| US7943586B2 (en) | 2003-06-09 | 2011-05-17 | The Trustees Of The University Of Pennsylvania | Antineoplastic agents targeted via glut transporters |
| EP1758887A1 (en) * | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US7091205B2 (en) | 2004-10-08 | 2006-08-15 | Yu Show Fu | Use of tetramethylpyrazine in the treatment of brain tumor |
| GB0513297D0 (en) | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| US20070275944A1 (en) | 2006-04-05 | 2007-11-29 | The Board Of Trustees Operating Michigan State University | Antioxidants and methods of their use |
| AR070317A1 (es) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
| WO2009111278A2 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| EP2141163A1 (de) * | 2008-07-02 | 2010-01-06 | Bayer Schering Pharma AG | Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| ES2668775T3 (es) * | 2009-06-10 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Compuestos tetracíclicos |
| US8293925B2 (en) * | 2009-09-21 | 2012-10-23 | Chemocentryx, Inc. | Pyrrolidinone carboxamide derivatives |
| JP6118808B2 (ja) | 2011-10-31 | 2017-04-19 | ザ メソジスト ホスピタル リサーチ インスティテュート | ヒトグリオームを治療するためのmao標的化/探索部分を含む化合物 |
-
2012
- 2012-10-31 JP JP2014540047A patent/JP6118808B2/ja not_active Expired - Fee Related
- 2012-10-31 EP EP12783818.3A patent/EP2804604A1/en not_active Withdrawn
- 2012-10-31 EP EP20189611.5A patent/EP3815685A3/en not_active Withdrawn
- 2012-10-31 AU AU2012376221A patent/AU2012376221A1/en not_active Abandoned
- 2012-10-31 KR KR1020147014835A patent/KR102110794B1/ko not_active Expired - Fee Related
- 2012-10-31 CN CN201280064763.1A patent/CN104136026B/zh not_active Expired - Fee Related
- 2012-10-31 CA CA2887928A patent/CA2887928A1/en not_active Abandoned
- 2012-10-31 WO PCT/US2012/062850 patent/WO2013151584A1/en not_active Ceased
- 2012-10-31 HK HK15103179.0A patent/HK1204547A1/xx unknown
-
2014
- 2014-04-30 US US14/266,729 patent/US10555936B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994029333A1 (en) * | 1993-06-07 | 1994-12-22 | The Wellcome Foundation Limited | Immunoreactive reagents employing monoamine oxidase |
| WO1998022110A1 (en) * | 1996-11-20 | 1998-05-28 | Virginia Tech Intellectual Properties, Inc. | Prodrugs for the selective inhibition of monoamine oxidase-b |
Also Published As
| Publication number | Publication date |
|---|---|
| US10555936B2 (en) | 2020-02-11 |
| JP2014534227A (ja) | 2014-12-18 |
| KR102110794B1 (ko) | 2020-05-15 |
| US20140323513A1 (en) | 2014-10-30 |
| WO2013151584A1 (en) | 2013-10-10 |
| EP2804604A1 (en) | 2014-11-26 |
| CN104136026A (zh) | 2014-11-05 |
| EP3815685A2 (en) | 2021-05-05 |
| HK1204547A1 (en) | 2015-11-27 |
| JP6118808B2 (ja) | 2017-04-19 |
| KR20140128943A (ko) | 2014-11-06 |
| CA2887928A1 (en) | 2013-10-10 |
| AU2012376221A1 (en) | 2014-06-19 |
| EP3815685A3 (en) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6652923B2 (ja) | クロロトキシンコンジュゲート及びその使用方法 | |
| US8853151B2 (en) | Pro-drug complexes and related methods of use | |
| US20100248371A1 (en) | Methods and compositions for modulating rad51 and homologous recombination | |
| AU2013362757B2 (en) | Radiosensitizer compounds for use in combination with radiation | |
| US20130317101A1 (en) | Singleton inhibitors of sumoylation enzymes and methods for their use | |
| JP2019501225A (ja) | B細胞リンパ腫2(bcl−2)及び関連タンパク質の阻害 | |
| US12377087B2 (en) | Compounds for the treatment of cancer | |
| US12186404B2 (en) | Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer | |
| CN104136026A (zh) | 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 | |
| US20110152252A1 (en) | Shiga toxin b-subunit/chemotherapeutics conjugates | |
| CN106232115A (zh) | 用于治疗抗性的癌症的预防或治疗性组合物 | |
| Hou et al. | GSH-activatable camptothecin prodrug-loaded gold nanostars coated with hyaluronic acid for targeted breast cancer therapy via multiple radiosensitization strategies | |
| JP2012012305A (ja) | 抗がん剤の作用増強剤 | |
| ES2991018T3 (es) | (N-(2-((2-bencilfenil)amino)-2-oxoetil)-L-naftamida) como agente terapéutico anticanceroso | |
| US20140296265A1 (en) | Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR | |
| JP6382964B2 (ja) | フタラジン誘導体 | |
| JP2014534227A5 (cg-RX-API-DMAC7.html) | ||
| US11325905B2 (en) | Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase | |
| HK40041905A (en) | Compound comprising a mao targeting/seeker moiety for treating human gliomas | |
| WO2022182655A2 (en) | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | |
| CN121240859A (zh) | 用于治疗健康状况的组合物和制备和使用小分子的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CI01 | Publication of corrected invention patent application |
Correction item: Applicant address Correct: Texas, USA False: Texas, USA Number: 45 Volume: 30 |
|
| CI02 | Correction of invention patent application |
Correction item: Applicant address Correct: Texas, USA False: Texas, USA Number: 45 Page: The title page Volume: 30 |
|
| ERR | Gazette correction |
Free format text: DELETE |
|
| RECT | Rectification | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230310 Address after: Texas, USA Patentee after: THE METHODIST Hospital Address before: Texas, USA Patentee before: THE METHODIST HOSPITAL Research Institute |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180302 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |